Holen Sie sich die Stockscreener-App
9.90
1.00%
-0.10
Schlusskurs vom Vortag:
$10.00
Offen:
$9.97
24-Stunden-Volumen:
11,695
Relative Volume:
0.38
Marktkapitalisierung:
$89.91M
Einnahmen:
$29.93M
Nettoeinkommen (Verlust:
$-545.30K
KGV:
-164.45
EPS:
-0.0602
Netto-Cashflow:
$3.38M
1W Leistung:
-0.40%
1M Leistung:
-10.57%
6M Leistung:
+53.25%
1J Leistung:
+51.84%
1-Tages-Spanne:
$9.80
$9.97
1-Wochen-Bereich:
$9.77
$10.09
52-Wochen-Spanne:
$4.52
$12.10
Immucell Corp Stock (ICCC) Company Profile
Firmenname
Immucell Corp
Sektor
Branche
Telefon
(207) 878-2770
Adresse
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
9.90 | 91.64M | 29.93M | -545.30K | 3.38M | -0.0602 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immucell Corp Aktie (ICCC) Neueste Nachrichten
ImmuCell CorporationCommon Stock (ICCC) Stock Price, News, Quote & History - FinancialContent
ImmuCell Q2 2026 slides: revenue gains offset by margin pressure - Investing.com
ImmuCell Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: ImmuCell posts strong Q2 2026 sales growth, shares fall - Investing.com
ImmuCell Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript - Sahm
ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
IMMUCELL CORP /DE/ Q2 2026: Revenue $7.19M, EPS $0.2— 10-Q Summary - TradingView
ImmuCell Corporation (ICCC) doubles profit on higher First Defense sales - Stock Titan
ImmuCell Plans About $4.5M Expansion for Calf Health Products - Stock Titan
ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calf-health company ImmuCell schedules Aug. 14 results webcast - Stock Titan
ImmuCell (ICCC) Expected to Release Earnings on Thursday - MarketBeat
ImmuCell Corp (ICCC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ImmuCell Corp (ICCC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ImmuCell Corp (ICCC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ICCC|ImmuCell Corp|Price:11.135|Chg%:+0.105 - TradingKey
ImmuCell Corp (ICCC) Cash Flow - TradingKey
ImmuCell Corp (ICCC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ImmuCell Corp (ICCC) Institutional Confidence - TradingKey
ImmuCell Corp (ICCC) Income Statement - TradingKey
ImmuCell Corp (ICCC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MSN Money - MSN
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH - RTTNews
ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand - Yahoo Finance
ImmuCell Corporation Files Form 8-K: Key Financial Data and Company Information for July 2026 - Minichart
ImmuCell reports 11.5% sales increase in second quarter - Investing.com
ImmuCell (ICCC) Reports Significant Growth in Quarterly Sales - GuruFocus
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results - The Manila Times
ImmuCell reports Q2 product sales up 11.5% to $7.2M; six‑month sales up 20.9% to $17.5M - TradingView
ImmuCell (ICCC) Q2 2026 sales hit $7.2M as six-month revenue climbs 20.9% - Stock Titan
ImmuCell sales jump 12% in Q2 as U.S. demand lifts calf products - Stock Titan
ImmuCell adds Jacee Lancaster to Commercial Team - Feedstuffs
ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70Inverse ETF Flow - dars.gov.et
ICCC's valuation remains premium: Is it worth overpaying for? - MSN
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell - Yahoo Finance
ImmuCell CEO buys $75,960 in common stock - Investing.com UK
Insider Buying: te Boekhorst Paul Francis Olivier Acquires Additional Shares of ImmuCell Corp (ICCC) - GuruFocus
Form 4 ImmuCell Corporation For: 22 June By Investing.com - Investing.com Nigeria
ImmuCell CEO buys $75,960 in common stock By Investing.com - Investing.com Canada
ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy - Stock Titan
ICCC's Valuation Remains Premium: Is it Worth Overpaying for? - The Globe and Mail
ImmuCell shareholders approve director elections and key proposals at annual meeting - Investing.com
ImmuCell (NASDAQ: ICCC) investors approve directors, pay plan, auditor - Stock Titan
Finanzdaten der Immucell Corp-Aktie (ICCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immucell Corp-Aktie (ICCC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BRIGHAM MICHAEL F | Director |
Mar 20 '26 |
Option Exercise |
5.84 |
25,000 |
146,000 |
229,752 |
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 03 '25 |
Buy |
5.02 |
6,077 |
30,536 |
9,785 |
| te Boekhorst Paul Francis Oliv | President and CEO |
Dec 02 '25 |
Buy |
4.87 |
3,708 |
18,053 |
3,708 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,781 |
4,740 |
| Tomsche David Scott | Director |
Nov 25 '25 |
Buy |
4.76 |
1,633 |
7,773 |
52,720 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):